Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 7
Submit an article Journal homepage
47
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma

A.D. Wechalekar Dept of Hematology/Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont., Canada
,
C.I. Chen Dept of Hematology/Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont., Canada
,
D. Sutton Dept of Hematology/Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont., Canada
,
D. Reece Dept of Hematology/Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont., Canada
,
M. Voralia Dept of Hematology/Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont., Canada
&
A.K. Stewart Dept of Hematology/Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont., CanadaCorrespondence[email protected]
Pages 1147-1149 | Received 24 Oct 2002, Published online: 03 Aug 2009

References

  • Kyle, R.A. (2001) "Update on the treatment of multiple myeloma", Oncologist 6, 119–124.
  • Singhal, S., Mehta, J., Desikan, R., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New England Journal of Medicine 341, 1565–1571.
  • Rajkumar, S.V., Fonseca, R., Dispenzieri, A., et al. (2000) "Thalidomide in the treatment of relapsed multiple myeloma", Mayo Clinic Proceedings 75, 897–901.
  • Parman, T., Wiley, M.J. and Wells, P.G. (1999) "Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity", Nature Medicine 5, 582–585.
  • Corral, L.G., Haslett, RA., Muller, G.W., et al. (1999) "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha", Journal of Immunology 163, 380–386.
  • Geitz, H., Handt, S. and Zwingenberger, K. (1996) "Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade", Immunophannacology 31, 213–221.
  • Bellamy, W.T., Richter, L., Frutiger, Y. and Grogan, T.M. (1999) "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies", Cancer Research 59, 728–733.
  • Haslett, P.A., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset", Journal of Experimental Medicine 187, 1885–1892.
  • Barlogie, B., Desikan, R., Eddlemon, P., et al. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients", Blood 98, 492–494.
  • Juliusson, G., Celsing, F., Turesson, I., et al. (2000) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", British Journal of Haematology 109, 89–96.
  • Rajkumar, S.V. and Witzig, T.E. (2000) "A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma", Cancer Treatment Reviews 26, 351–362.
  • Schreiber, S., Ackermann, J., Obermair, A., et al. (2000) "Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization", British Journal of Haematology 110, 605–609.
  • Zangari, M., Anaissie, E., Barlogie, B., et al. (2001) "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy", Blood 98, 1614–1615.
  • Kneller, A., Raanani, P., Hardan, I., Avigdor, A., Levi, I., Berkowicz, M. and Ben-Bassat, I. (2000) "Therapy with thalidomide in refractory multiple myeloma patients—the revival of an old drug", British Journal of Haematology 108, 391–393.
  • Dune, B.M. and Stephan, D.E. (2001) "Low dose thalidomide alone and in combination: long term follow up", Blood 98, 688, (Abstract).
  • Grosbois, B., Bellissant, E., Moreau, P., Attal, M. and Zerbib, R. (2001) "Thalidomide (Thal) in treatment of advanced multiple myeloma. A prospective study of 120 patients", Blood 98, 689, (Abstract).
  • Johnston, RE. and Abdalla, S.H. (2002) "Thalidomide in low dose is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukemia", Leukemia and Lymphoma 43, 351–354.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.